Clearmind Medicine has submitted a formal response to the U.S. Department of Health and Human Services Request for Information on addiction treatment innovations as part of the Great American Recovery Initiative. The company highlights its proprietary MEAI-based candidate CMND-100, a non-hallucinogenic neuroplastogen for alcohol use disorder and binge behaviors, emphasizing that AUD affects approximately 10% of the U.S. population with only 1 in 10 receiving treatment. Clearmind proposes an at-home, scalable solution with low abuse potential designed to engage neural pathways such as 5-HT1A to support moderation and long-term recovery. CEO Dr. Adi Zuloff-Shani stated that research at Yale and Johns Hopkins indicates MEAI is well-positioned to lead in these efforts, and the submission underscores the company's commitment to science-driven, non-opioid solutions.
Clearmind Medicine Inc. Common SharesCompany submits formal response to HHS RFI for addiction treatment, potentially influencing regulatory pathway for CMND-100.